March 9, 2015 – WASHINGTON, DCThe Association of Clinical Research Organizations, whose members account for approximately two-thirds of contract clinical development services, held the inaugural meeting of the previously announced CRO Forum in Washington, DC. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma Inc.
The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research.
ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system. The Forum selected senior subject matter experts to serve as liaisons to each of these workstreams. The liaisons will be supported by working groups consisting of subject matter experts from across the Forum membership.
“With the ever-increasing role CROs are playing across the drug development spectrum, and the innovation we are bringing to the process, we look forward to entering a meaningful dialogue with TransCelerate,” said ACRO Chairman Jamie Macdonald, CEO of INC Research. “As the relationship progresses, we anticipate providing CRO industry input into additional workstreams as well as suggesting possible new workstreams for TransCelerate’s consideration.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.